Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) and Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.
Analyst Ratings
This is a breakdown of current ratings and price targets for Allarity Therapeutics and Halozyme Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allarity Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Halozyme Therapeutics | 1 | 2 | 9 | 1 | 2.77 |
Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 1,084.42%. Halozyme Therapeutics has a consensus target price of $99.55, indicating a potential downside of 20.76%. Given Allarity Therapeutics’ higher probable upside, equities analysts clearly believe Allarity Therapeutics is more favorable than Halozyme Therapeutics.
Insider and Institutional Ownership
11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Allarity Therapeutics and Halozyme Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allarity Therapeutics | $320,000.00 | 43.03 | -$11.23 million | ($0.78) | -1.11 |
| Halozyme Therapeutics | $1.40 billion | 10.21 | $316.89 million | $3.35 | 37.50 |
Halozyme Therapeutics has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Allarity Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.
Profitability
This table compares Allarity Therapeutics and Halozyme Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allarity Therapeutics | N/A | -152.77% | -46.50% |
| Halozyme Therapeutics | 24.86% | 260.98% | 23.91% |
Summary
Halozyme Therapeutics beats Allarity Therapeutics on 13 of the 15 factors compared between the two stocks.
About Allarity Therapeutics
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
